Ezetimibe-Simvastatin Therapy Reduce Recurrent Ischemic Stroke Risks in Type 2 Diabetic Patients | Zendy

ChiHung Liu | Zendy; TienHsing Chen | Zendy; MingShyan Lin | Zendy; MingJui Hung | Zendy; Chang-Ming Chung | Zendy; WenJin Cherng | Zendy; TsongHai Lee | Zendy; YuSheng Lin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ezetimibe-Simvastatin Therapy Reduce Recurrent Ischemic Stroke Risks in Type 2 Diabetic Patients

Author(s) -

ChiHung Liu,

TienHsing Chen,

MingShyan Lin,

MingJui Hung,

Chang-Ming Chung,

WenJin Cherng,

TsongHai Lee,

YuSheng Lin

Publication year - 2016

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2016-1831

Subject(s) - ezetimibe , medicine , simvastatin , hazard ratio , stroke (engine) , myocardial infarction , statin , diabetes mellitus , confidence interval , atorvastatin , acute coronary syndrome , type 2 diabetes , gastroenterology , endocrinology , mechanical engineering , engineering

Statin is the main lipid-lowering therapy for type 2 diabetes mellitus patients. Recent evidence suggested the cardiovascular protective effects of ezetimibe-simvastatin in acute coronary syndrome patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research